

November 5, 2024

**Supplementary Documents of Consolidated
Financial Results for the Second Quarter of FY2024
(from April 1, 2024 to March 31, 2025)**



Securities code : 4886 (TSE)

ASKA Pharmaceutical Holdings Co., Ltd.

Highlight

2Q FY2024 (Consolidated)

Net sales

✓ **32.3 billion yen, up 2.3% YOY**

Increased sales due to growth in the pharmaceutical business and the veterinary pharmaceutical business resulted in record-high sales.

Cost of sales

✓ **16.4 billion yen, improved 1.2 percentage points YOY**

Product mix improved the cost of sales ratio due to growth in Brand-name drugs such as RELUMINA, RIFXIMA, and other products.

SG&A expenses

✓ **12.5 billion yen, up 0.5 percentage points YOY**

The ratio of SG&A expenses to sales increased due to increased costs associated with R&D progress despite the decreased depreciation.

Operating profit

✓ **3.3 billion yen, up 9.5% YOY**

Increased sales and gross profit boosted profits.

FY2024 Consolidated Financial Forecast *No changes from the forecast previously announced

Performance forecast

✓ **Net sales 63.0 billion yen, up 0.2% YOY**

✓ **Operating profit 6.7 billion yen, up 3.1% YOY**

Statements of Income (Consolidated)

(Millions of yen)	FY2023 Apr - Sep Actual	FY2024 Apr - Sep Actual	Actual +/-	Growth +/-
Net sales	31,648	32,371	722	2.3%
Operating profit	3,055	3,345	290	9.5%
Ordinary profit	3,096	3,312	216	7.0%
Profit attributable to owners of parent	4,129	2,560	-1,569	-38.0%

Major factors for increases/decreases

- ✓ While the outlook remains uncertain due to volatile international situations and rising raw material and resource prices, net sales in the Group's business increased due to growth in the pharmaceutical business and the veterinary pharmaceutical business.
- ✓ In terms of profits, despite an increase in expenses such as R&D expenses, both of operating profit and ordinary profit were up from the same period of the previous year since efforts were made to improve costs.
- ✓ Profit attributable to owners of parent decreased by 38.0% YoY, due to a reaction to the recording of a gain on sales of investment securities as extraordinary income in the previous fiscal year.

Net Sales by Business (Consolidated)

(Millions of yen)	FY2023 Apr - Sep Actual	FY2024 Apr - Sep Actual	Breakdown	Actual +/-	Growth +/-
Pharmaceutical business	28,404	28,617	88.4%	212	0.7%
Animal health Business	3,162	3,640	11.2%	478	15.1%
Other businesses	80	113	0.4%	33	39.9%
Total	31,648	32,371	100.0%	722	2.3%

Major factors for increased sales

- ✓ The pharmaceutical business showed favorable trends overall despite the impact of the annual NHI drug price revisions. In addition to the steady growth of RELUMINA, DroEthi continued to significantly drive performance from the previous year. In addition, sales of THYRADIN and RIFXIMA also grew steadily.
- ✓ In the animal health business, sales of feed additives and companion animal pharmaceuticals largely increased from the previous year.

Sales of Main Products (Pharmaceutical Business)

(Millions of yen)

Area	Category	Products (generic name)	FY2023 Apr - Sep	FY2024 Apr - Sep		FY2024		Reference	Notes
			Actual	Actual	YOY	Forecast	YOY	Initial Forecast	
Internal Medicine	AG	CANDESARTAN ^{*1} (candesartan)	4,952	4,302	-13.1%	8,388	-12.6%	8,626	The NHI drug price declined, but sales volume remained almost same
	Brand-name	THYRADIN (levothyroxine)	4,000	4,052	1.3%	7,861	0.0%	8,018	Slight increases continue over the long term
	Brand-name	RIFXIMA (rifaximin)	2,997	3,227	7.7%	6,288	7.2%	6,117	Sales grew steadily as the Guideline penetrated
	Brand-name	MERCAZOLE (thiamazole)	776	792	2.1%	1,526	0.3%	1,510	Progress as expected
	Generic	AMLODIPINE (amlodipine)	430	400	-7.0%	784	-6.7%	806	Impacted by the NHI drug price reductions
Obstetrics and Gynecology	Brand-name	RELUMINA (relugolix)	5,186	5,413	4.4%	10,726	8.3%	11,251	Focused on expanding our share in the endometriosis market
	Generic	DroEthi (norethisterone/ethinylestradiol)	2,909	3,589	23.3%	7,070	15.4%	5,990	Significant progress beyond expectations
	AG	FREWELL (drospirenone/ethinylestradiol)	1,663	1,550	-6.8%	3,026	-8.4%	3,101	The NHI drug price down, but sales volume increased.
	Brand-name	LUTEUM (progesterone)	876	1,143	30.5%	2,341	15.4%	2,106	Sales continued to remain strong
	Brand-name	ANGE (levonorgestrel/ethinylestradiol)	367	350	-4.7%	746	2.9%	790	Focused on strengthening promotion
	Brand-name	MAGSENT ^{*2} (magnesium sulfate)	355	376	5.9%	713	1.0%	665	Progress as expected
Urol- ogy	Generic	LEUPRORELIN ^{*3} (leuprorelin)	2,321	2,037	-12.2%	3,938	-11.1%	3,962	Impacted by the NHI drug price reductions

* 1 Including fixed dose combination

* 3 1.88mg formulation is only for gynecological indications but combined with 3.75mg formulation

* 2 Total value of magnesium sulfate preparation

Sales by Major Business Field (Animal Health Business)

Business field	FY2023 Apr - Sep	FY2024 Apr - Sep		FY2024		Reference
	Actual	Actual	YOY	Forecast	YOY	Initial Forecast
Feed additives Mixed feed Feed materials	1,873	2,275	21.5%	4,260	5.4%	4,031
Veterinary pharmaceuticals (livestock and fisheries + *CA)	1,189	1,339	12.6%	2,590	4.2%	2,534


Major factors for increased sales

- ✓ In the second quarter of FY2024, sales increased due to increased demand for feed additives and growth in companion animal pharmaceuticals.
- ✓ For the full year of FY2024, it is expected that sales of feed additives and veterinary pharmaceuticals for companion animals will grow.

* Companion Animal

Sales Ratio / Sales Proportion of Brand-name Drugs

Sales Ratio (2Q FY2024)




The total may not add up to 100 because the figures are rounded to the second decimal place.


Sales Proportion of Brand-name Drugs

■ Brand-name drugs ■ Generic drugs

2Q FY2023



2Q FY2024




The product mix improved due to growth in RELUMINA, RIFXIMA, and THYRADIN, resulting in a 1.8 percentage point increase in the ratio of brand-name drugs to sales.

Note: We have reviewed the products in the Internal Medicine category and reclassified some products from 'Others' to 'Internal Medicine (Gastrointestinal and Thyroid)'.

R&D Status

Trend of R&D expenses



* Revised from the initial forecast of 5,575 million yen for R&D expenses

As of November 5, 2024

Development code (Generic name) / Indication	Phase
LF111 (drospirenone) Contraception	Filed
(Option agreement) Treatment for PMS/PMDD	Ph II (IIT *1)
AKP-022 (Relugolix combination tablet) Uterine fibroids	Preparing for Ph III
AKP-022 (Relugolix combination tablet) Endometriosis	Preparing for clinical trials
TRM-270 (adhesion barrier) (Gastroenterology and Ob/Gyn)	Ph III
AKP-009 (ludaterone acetate) Benign prostatic hyperplasia	Ph II*2
AKP-017 (transnasal testosterone) (Urology)	Preparing for clinical trials
AKP-021 (mPGES-1 Inhibitor) (Urology)	Preparing for clinical trials

*1 Investigator-initiated clinical trial

*2 Further steps are being considered in response to the results of the re-conducted Phase I trial